Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

D. F. Heitjan, D. A. Asch, Riju Ray, Margaret Rukstalis, Freda Patterson, C. Lerman

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions.

Original languageEnglish (US)
Pages (from-to)391-399
Number of pages9
JournalPharmacogenomics Journal
Volume8
Issue number6
DOIs
StatePublished - Nov 24 2008

Fingerprint

Bupropion
Withholding Treatment
Smoking Cessation
Cost-Benefit Analysis
Nicotine
Tobacco Use Cessation
Costs and Cost Analysis
Tobacco Use Disorder
Genetic Testing
Therapeutics
Health Care Costs
Pharmacogenomic Testing
Varenicline
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Pharmacology

Cite this

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. / Heitjan, D. F.; Asch, D. A.; Ray, Riju; Rukstalis, Margaret; Patterson, Freda; Lerman, C.

In: Pharmacogenomics Journal, Vol. 8, No. 6, 24.11.2008, p. 391-399.

Research output: Contribution to journalArticle

Heitjan, D. F. ; Asch, D. A. ; Ray, Riju ; Rukstalis, Margaret ; Patterson, Freda ; Lerman, C. / Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. In: Pharmacogenomics Journal. 2008 ; Vol. 8, No. 6. pp. 391-399.
@article{fea7b519ad404b9683126b95785ddf73,
title = "Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment",
abstract = "We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions.",
author = "Heitjan, {D. F.} and Asch, {D. A.} and Riju Ray and Margaret Rukstalis and Freda Patterson and C. Lerman",
year = "2008",
month = "11",
day = "24",
doi = "10.1038/sj.tpj.6500492",
language = "English (US)",
volume = "8",
pages = "391--399",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

AU - Heitjan, D. F.

AU - Asch, D. A.

AU - Ray, Riju

AU - Rukstalis, Margaret

AU - Patterson, Freda

AU - Lerman, C.

PY - 2008/11/24

Y1 - 2008/11/24

N2 - We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions.

AB - We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions.

UR - http://www.scopus.com/inward/record.url?scp=56349111039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349111039&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500492

DO - 10.1038/sj.tpj.6500492

M3 - Article

VL - 8

SP - 391

EP - 399

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 6

ER -